Compile Data Set for Download or QSAR

Found 3 hits of ic50 for monomerid = 50101765   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101765 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17| Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	7	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101765 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17| Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	63	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-IIb/beta-3 (Homo sapiens (Human))	BDBM50101765 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(CCC(=O)NC2=NCCCN2)s1)NC(=O)OCc1ccccc1 |t:17| Show InChI InChI=1S/C23H27N5O6S/c29-19(28-22-24-11-4-12-25-22)10-8-16-7-9-18(35-16)20(30)26-13-17(21(31)32)27-23(33)34-14-15-5-2-1-3-6-15/h1-3,5-7,9,17H,4,8,10-14H2,(H,26,30)(H,27,33)(H,31,32)(H2,24,25,28,29)/t17-/m0/s1	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	4.50E+3	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair